['dry eye syndrome']
['rgn-259', 'placebo']

        Inclusion Criteria:

          -  Be at least 18 years of age;

          -  Provide written informed consent;

          -  Have a subject reported history of dry eye for at least 6 months

          -  Have a history of use or desire to use eye drops for dry eye symptoms within 6 months

          -  Have a Schirmer's Test score of ≤10mm and ≥1mm

          -  Have a Tear Film Break-Up Time (TFBUT) ≤10 seconds

          -  Have a corneal fluorescein staining score of ≥2 in at least one region of the cornea

        Exclusion Criteria:

          -  Have any clinically significant slit-lamp findings at Visit 1 that may include active
             blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation or active
             ocular allergies that require therapeutic treatment, and/or in the opinion of the
             investigator may interfere with study parameters;

          -  Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active
             ocular inflammation at Visit 1;

          -  Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses
             during the study;

          -  Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the
             last 6 months;

          -  Have an IOP > 25 mmHg at Visit 1;

          -  Have any planned ocular and/or lid surgeries over the study period;

          -  Be using or anticipate using temporary punctal plugs during the study that have not
             been stable within 30 days of Visit 1;

          -  Be currently taking any topical ophthalmic prescription (including medications for
             glaucoma) or over-the-counter (OTC) solutions, artificial tears, gels or scrubs, and
             cannot discontinue these medications for the duration of the trial (excluding
             medications allowed for the conduct of the study);

          -  Have corrected visual acuity greater than or equal to logMAR +0.7 as assessed by Early
             Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1;
      